ArticleSAGE open medicine2026
SLC16A1 lactylation links epimetabolic reprogramming of triglycerides (50:3 and 50:1) to blood pressure regulation.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the causal relationship between SLC16A1 lactylation modification and systolic blood pressure (SBP) and diastolic blood pressure (DBP), as well as the potential mediating role of lipidomics-triglyceride (50:3/50:1) in this association. Methods: This study combines eQTL data and lactylation modifications to identify 16 associated genes, using Mendelian randomisation (MR) to assess their effects on SBP and DBP. It also employs summary-data-based Mendelian randomisation (SMR) for validation and lipidomics analysis to explore the effect of SLC16A1 lactylation on triglyceride (TG) subtypes (50:3/50:1). Finally, mediation analysis quantifies the role of triglyceride subtypes in the link between SLC16A1 lactylation and blood pressure changes. Results: SLC16A1 lactylation modification negatively correlates with SBP ( Conclusion: This study reveals that SLC16A1 lactylation modification might regulate SBP and DBP by suppressing the levels of TG(50:3) and TG(50:1), offering potential therapeutic targets for precision interventions in metabolic hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.